IL310590A - Methods of treating migraine with MNK inhibitors - Google Patents
Methods of treating migraine with MNK inhibitorsInfo
- Publication number
- IL310590A IL310590A IL310590A IL31059024A IL310590A IL 310590 A IL310590 A IL 310590A IL 310590 A IL310590 A IL 310590A IL 31059024 A IL31059024 A IL 31059024A IL 310590 A IL310590 A IL 310590A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- treating migraine
- mnk inhibitors
- mnk
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229882P | 2021-08-05 | 2021-08-05 | |
| PCT/US2022/039529 WO2023014943A1 (en) | 2021-08-05 | 2022-08-05 | Methods of treating migraine with mnk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310590A true IL310590A (en) | 2024-04-01 |
Family
ID=85154787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310590A IL310590A (en) | 2021-08-05 | 2022-08-05 | Methods of treating migraine with MNK inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250205244A1 (https=) |
| EP (1) | EP4380566A4 (https=) |
| JP (1) | JP2024528982A (https=) |
| KR (1) | KR20240055743A (https=) |
| CN (1) | CN118076354A (https=) |
| AU (1) | AU2022324472A1 (https=) |
| CA (1) | CA3228265A1 (https=) |
| IL (1) | IL310590A (https=) |
| MX (1) | MX2024001560A (https=) |
| WO (1) | WO2023014943A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| CN116735759B (zh) * | 2023-08-14 | 2023-11-07 | 南京威凯尔生物医药科技有限公司 | 一种高效液相色谱法检测乌布吉泮中间体及其对映体杂质的方法 |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
| WO2026006453A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Solid dispersion formulations of mnk inhibitors |
| WO2026006442A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Deuterated mnk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080039450A1 (en) * | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| US10280168B2 (en) * | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| TW201831479A (zh) * | 2017-01-20 | 2018-09-01 | 德商拜耳製藥公司 | 經取代二氫咪唑并吡啶二酮 |
| US20190388425A1 (en) * | 2017-01-20 | 2019-12-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
-
2022
- 2022-08-05 EP EP22853939.1A patent/EP4380566A4/en active Pending
- 2022-08-05 CA CA3228265A patent/CA3228265A1/en active Pending
- 2022-08-05 IL IL310590A patent/IL310590A/en unknown
- 2022-08-05 WO PCT/US2022/039529 patent/WO2023014943A1/en not_active Ceased
- 2022-08-05 KR KR1020247007155A patent/KR20240055743A/ko active Pending
- 2022-08-05 AU AU2022324472A patent/AU2022324472A1/en active Pending
- 2022-08-05 MX MX2024001560A patent/MX2024001560A/es unknown
- 2022-08-05 CN CN202280062076.XA patent/CN118076354A/zh active Pending
- 2022-08-05 US US18/294,823 patent/US20250205244A1/en active Pending
- 2022-08-05 JP JP2024506658A patent/JP2024528982A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240055743A (ko) | 2024-04-29 |
| AU2022324472A1 (en) | 2024-02-15 |
| JP2024528982A (ja) | 2024-08-01 |
| EP4380566A4 (en) | 2025-08-27 |
| WO2023014943A1 (en) | 2023-02-09 |
| MX2024001560A (es) | 2024-06-26 |
| EP4380566A1 (en) | 2024-06-12 |
| US20250205244A1 (en) | 2025-06-26 |
| CA3228265A1 (en) | 2023-02-09 |
| CN118076354A (zh) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310590A (en) | Methods of treating migraine with MNK inhibitors | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| PT4181920T (pt) | Inibidor de kat6 e combinações para o tratamento do cancro da mama | |
| IL318169A (en) | Apol1 inhibitors and methods of use are the same | |
| MX2020000367A (es) | Inhibidores de rad51. | |
| IL312348A (en) | HIF-2ALPHA inhibitors and methods of using it | |
| ZA202206163B (en) | Methods of treating coronavirus | |
| IL299206A (en) | Methods for treating cancer using heteroaryl-biphenyl amide derivatives | |
| EP4185386C0 (en) | HETEROCYCLIC TEAD INHIBITORS FOR THE TREATMENT OF CANCER | |
| GB202416189D0 (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| SG11202009966SA (en) | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer | |
| IL325326A (en) | Cancer treatment method with indulin inhibitors of kif18a | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| HK40111263A (en) | Methods of treating migraine with mnk inhibitors | |
| IL307291A (en) | Methods for treating inflammation | |
| WO2019157085A3 (en) | INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS | |
| EP4444419A4 (en) | METHODS OF TREATING LYMPHOEDEMA | |
| PL3851261T3 (pl) | Sposób zapobiegawczej obróbki drewna | |
| IL272390A (en) | Cancer treatment methods | |
| PT3955933T (pt) | Tratamento da enxaqueca | |
| IL308377A (en) | Methods for treating skin and muscle inflammation |